Effect of gemfibrozil and rifampicin on the pharmacokinetics of selexipag and its active metabolite in healthy subjects

AIMS: Based on in vitro data, there is evidence to suggest that cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679. The present study evaluated the possible pharmacokinetic interactions of selexipag with gemfibrozil, a strong CYP2C8 inhibitor,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Clin Pharmacol
Hlavní autoři: Bruderer, Shirin, Petersen‐Sylla, Marc, Boehler, Margaux, Remeňová, Tatiana, Halabi, Atef, Dingemanse, Jasper
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Drug Interactions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698574/
https://ncbi.nlm.nih.gov/pubmed/28715853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13379
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky